Investigating how adropin therapy affects dementia in mouse models
An investigation of the response of preclinical mouse models of dementia to adropin therapy
This study is looking at how a treatment called adropin might help improve brain function and memory in mice with dementia, especially Alzheimer's, to find new ways to support brain health in older adults.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Saint Louis University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10891959 on NIH RePORTER |
What this research studies
This research explores the effects of adropin therapy on preclinical mouse models of dementia, particularly focusing on Alzheimer's disease and related conditions. The study aims to understand how increasing levels of adropin, a peptide linked to brain function, can potentially reverse cognitive decline associated with aging. By examining the relationship between adropin levels and cognitive abilities in these models, researchers hope to uncover new treatment avenues for dementia. The findings could lead to innovative therapies that improve brain health in older adults.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults, particularly those aged 70 years and above, who are experiencing cognitive decline or are at risk for Alzheimer's disease.
Not a fit: Patients who are younger than 70 years or do not have any cognitive impairment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow down or prevent cognitive decline in patients with dementia.
How similar studies have performed: Previous studies have shown promising results in using adropin to influence cognitive function, suggesting that this approach may be viable for treating dementia.
Where this research is happening
Saint Louis, United States
- Saint Louis University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Butler, Andrew Alistair — Saint Louis University
- Study coordinator: Butler, Andrew Alistair
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.